-
ICD-10-CM Codes
›
-
G00-G99
Diseases of the nervous system
›
-
G10-G14
Systemic atrophies primarily affecting the central nervous system
›
-
G13-
Systemic atrophies primarily affecting central nervous system in diseases classified elsewhere
›
-
2021 ICD-10-CM Diagnosis Code G13.2
2021 ICD-10-CM Diagnosis Code G13.2
Systemic atrophy primarily affecting the central nervous system in myxedema
2016 2017 2018 2019 2020 2021 Billable/Specific Code Manifestation Code
- G13.2 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.
- Short description: Systemic atrophy primarily affecting the cnsl in myxedema
- The 2021 edition of ICD-10-CM G13.2 became effective on October 1, 2020.
- This is the American ICD-10-CM version of G13.2 - other international versions of ICD-10 G13.2 may differ.
ICD-10-CM Coding Rules
- G13.2 describes the manifestation of an underlying disease, not the disease itself.
Code FirstCode First Help
Certain conditions have both an underlying etiology and multiple body system manifestations due to the underlying etiology. For such conditions, ICD-10-CM has a coding convention that requires the underlying condition be sequenced first followed by the manifestation. Wherever such a combination exists there is a "use additional code" note at the etiology code, and a "code first" note at the manifestation code. These instructional notes indicate the proper sequencing order of the codes, etiology followed by manifestation. In most cases the manifestation codes will have in the code title, "in diseases classified elsewhere." Codes with this title are a component of the etiology/manifestation convention. The code title indicates that it is a manifestation code. "In diseases classified elsewhere" codes are never permitted to be used as first listed or principle diagnosis codes. They must be used in conjunction with an underlying condition code and they must be listed following the underlying condition.
The following code(s) above
G13.2 contain annotation back-references
Annotation Back-References
In this context, annotation back-references refer to codes that contain:
- Applicable To annotations, or
- Code Also annotations, or
- Code First annotations, or
- Excludes1 annotations, or
- Excludes2 annotations, or
- Includes annotations, or
- Note annotations, or
- Use Additional annotations
that may be applicable to
G13.2:
- 056 Degenerative nervous system disorders with mcc
- 057 Degenerative nervous system disorders without mcc
Convert G13.2 to ICD-9-CM
Code History
- 2016 (effective 10/1/2015): New code (first year of non-draft ICD-10-CM)
- 2017 (effective 10/1/2016): No change
- 2018 (effective 10/1/2017): No change
- 2019 (effective 10/1/2018): No change
- 2020 (effective 10/1/2019): No change
- 2021 (effective 10/1/2020): No change
Code annotations containing back-references to G13.2:
ICD-10-CM Codes Adjacent To G13.2
G12.22 Progressive bulbar palsy
G12.23 Primary lateral sclerosis
G12.24 Familial motor neuron disease
G12.25 Progressive spinal muscle atrophy
G12.29 Other motor neuron disease
G12.8 Other spinal muscular atrophies and related syndromes
G12.9 Spinal muscular atrophy, unspecified
G13 Systemic atrophies primarily affecting central nervous system in diseases classified elsewhere
G13.0 Paraneoplastic neuromyopathy and neuropathy
G13.1 Other systemic atrophy primarily affecting central nervous system in neoplastic disease
G13.2
Systemic atrophy primarily affecting the central nervous system in myxedema
G13.8 Systemic atrophy primarily affecting central nervous system in other diseases classified elsewhere
G21 Secondary parkinsonism
G21.0 Malignant neuroleptic syndrome
G21.1 Other drug-induced secondary parkinsonism
G21.11 Neuroleptic induced parkinsonism
G21.19 Other drug induced secondary parkinsonism
G21.2 Secondary parkinsonism due to other external agents
G21.3 Postencephalitic parkinsonism
Reimbursement claims with a date of service on or after October 1, 2015 require the use of ICD-10-CM codes.
